Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Inclusion Criteria

• Histologically proven advanced or metastatic solid cancer
• Measurable disease, evaluable disease or elevation of a relevant soluble tumor marker (e.g., CEA, PSA, CA125)
• Age of 18 years or older
• ECOG performance status of 0 or 1
• Resolution of all acute AEs resulting from prior cancer therapies to NCI CTCAE Grade ≤ 1 or baseline (except alopecia)
• Adequate organ function
• Willing and able to consent for self to participate in study

Exclusion Criteria

• Prior treatment with TRC105
• Serious dose-limiting toxicity related to prior bevacizumab
• Current treatment on another therapeutic clinical trial
• Receipt of an investigational agent within 28 days of starting study treatment
• Prior surgery (including open biopsy) within 28 days of starting the study treatment
• Prior radiation therapy or systemic therapy within 21 days of starting the study treatment
• Minor surgical procedures such as fine needle aspirations, Mediport placement or core biopsies within 7 days of study treatment
• Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despite optimal therapy (initiation or adjustment of BP medication prior to study entry allowed provided that the average of 3 BP readings at a visit prior to enrollment is ½ teaspoon bright red blood) within 6 months of starting study treatment
• Open wounds or unhealed fractures within 28 days of starting study treatment
• History of peptic ulcer disease or erosive gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment
• Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
• Pregnancy or breastfeeding